Cited by 283Bone health and osteoporosis researchHormonal and reproductive studiesBone Metabolism and Diseases

Differential Effects of Androgens and Estrogens on Bone Turnover in Normal Men

Leder, Benjamin Z., LeBlanc, Karen M., Schoenfeld, David A., Eastell, Richard, Finkelstein, Joel S.·2003·The Journal of Clinical Endocrinology & Metabolism

Abstract

The physiologic role of androgens and estrogens in the maintenance of normal bone turnover in men is a fundamental issue in bone biology. To address this question, we randomized 70 men between the ages of 20 and 44 yr to receive one of three treatment regimens. Group 1 (n = 25) received a GnRH analog (goserelin acetate 3.6 mg by sc injection every 4 wk) alone for 12 wk to suppress endogenous gonadal steroids to prepubertal levels. Group 2 (n = 22) received goserelin plus transdermal testosterone (Androderm 5 mg topically daily) to normalize circulating testosterone and estradiol levels. Group 3 (n = 23) received goserelin plus testosterone plus an aromatase inhibitor (anastrozole 1 mg orally daily) to induce selective estrogen deficiency. The selective effects of androgens and estrogens on skeletal homeostasis were then assessed by measuring changes in biochemical markers of bone turnover and analyzing the between-group differences. Bone resorption markers increased in both the hypogonadal group (group 1) and in the group with selective estrogen deficiency (group 3). Urinary deoxypyridinoline excretion increased more in group 1 than in group 3 (P = 0.023), suggesting a significant effect of androgens on bone resorption, whereas serum N-telopeptide levels increased more in group 3 than in group 2 (P = 0.037), suggesting a significant effect of estrogen on bone resorption. Bone formation markers initially declined in all groups and then increased in groups 1 and 3. The between-group comparisons were consistent for all formation markers. Bone formation markers increased more in group 1 than in group 2 (P = 0.001, 0.037, 0.005 for osteocalcin, carboxy-terminal propeptide of type I procollagen, and amino-terminal propeptide of type I procollagen, respectively). Bone formation markers also increased more in group 1 than in group 3 but these differences were not statistically significant (P = 0.065 0.073, 0.099 for osteocalcin, carboxy-terminal propeptide of type I procollagen, and amino-terminal propeptide of type I procollagen, respectively). Taken together, these data suggest that both androgens and estrogens play independent and fundamental roles in regulating bone resorption in men. These data also suggest that androgens may play an important role in the regulation of bone formation in men.

Integrity signals

Registry

Crossref · 10.1210/jc.2002-021036

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Aromatase inhibition results in a dramatic reduction of tumor estrogen concentrations.

    “It is well known that aromatase inhibition results in a dramatic reduction of tumor estrogen concentrations [66].”

    From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [66]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Leder, B. Z., LeBlanc, K. M., Schoenfeld, D. A., Eastell, R., & Finkelstein, J. S.
Affiliations
  • Massachusetts General Hospital (US)
  • Northern General Hospital (GB)
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2003-01
Volume
88
Issue
1
Pages
204-210
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2143514874
Cited by
283
References
41
Citations by year
2026: 3 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 9 · 2021: 4 · 2020: 11 · 2019: 7 · 2018: 9 · 2017: 10 · 2016: 17 · 2015: 6 · 2014: 15 · 2013: 16 · 2012: 17
FWCI
17.30
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5f32ar008574-02)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K24DK02759, K24DK002759)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (F32-AR08574)
  • National Center for Research Resources (K23 RR 16310, M01RR001066, K23RR016310, RR-1066)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
androgens, estrogen, bone turnover, bone resorption, bone formation, testosterone, estradiol, aromatase inhibition, goserelin, GnRH analogues, hypogonadism, men, bone turnover markers, deoxypyridinoline, N-telopeptide, osteocalcin, type I procollagen, skeletal homeostasis
MeSH terms
Anastrozole, Administration, Cutaneous, Adult, Androgens, Bone Resorption, Drug Synergism, Enzyme Inhibitors, Estrogens, Hormones, Humans, Injections, Subcutaneous, Gonadotropin-Releasing Hormone, Male, Nitriles, Osteogenesis, Testosterone, Triazoles, Biomarkers, Bone Remodeling, Goserelin, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review